Diabetes

Top Story

EXSCEL: Exenatide meets primary safety objective for CV risk in type 2 diabetes

May 23, 2017

Top-line results from the EXSEL trial show the GLP-1 receptor agonist exenatide extended release met the primary safety objective of non-inferiority for major adverse cardiac events in patients with type 2 diabetes when compared with placebo, Astra Zeneca announced in a press release.

The Exenatide Study of Cardiovascular Event Lowering trial compared the effect of once-weekly exenatide extended release (Bydureon) added to usual care with placebo on the risk for the composite endpoint of CV death, non-fatal myocardial infarction or non-fatal stroke, in adults with type-2 diabetes at a wide range of CV risk. The EXSCEL trial is the largest and most inclusive patient population of any CV outcomes trial of the GLP-1 receptor agonist class conducted to date, including more than 14,000 patients from 35 countries, according to the release.

Meeting News

New therapies offer options for patients with diabetes, heart failure

May 6, 2017
AUSTIN, Texas — New anti-diabetic therapies offer options for patients with type 2 diabetes and heart failure, whereas several ongoing and longer-term studies are…
Meeting News

Resveratrol may reduce arterial stiffness in patients with diabetes

May 5, 2017
Resveratrol reversed arterial stiffness in patients with type 2 diabetes, according to an abstract presented at the American Heart Association’s Arteriosclerosis…

Trial to study subcutaneous ICD in patients with diabetes, MI commences

April 29, 2017
An international trial to study the survival benefit of a subcutaneous implantable cardioverter defibrillator system has begun enrolling patients, according to a press…

EXSCEL: Exenatide meets primary safety objective for CV risk in type 2 diabetes

May 23, 2017
Top-line results from the EXSEL trial show the GLP-1 receptor agonist exenatide extended release met the primary safety objective of non-inferiority…

Meeting News

New therapies offer options for patients with diabetes, heart failure

May 6, 2017
AUSTIN, Texas — New anti-diabetic therapies offer options for patients with type 2 diabetes and heart failure, whereas several ongoing and…

Meeting News

Resveratrol may reduce arterial stiffness in patients with diabetes

May 5, 2017
Resveratrol reversed arterial stiffness in patients with type 2 diabetes, according to an abstract presented at the American Heart…

Trial to study subcutaneous ICD in patients with diabetes, MI commences

April 29, 2017
An international trial to study the survival benefit of a subcutaneous implantable cardioverter defibrillator system has begun enrolling patients…

In the Journals

Younger adults experiencing more ischemic strokes, CV risk factors

April 26, 2017
Even with the decrease of stroke mortality rates in older adults, hospitalization rates for ischemic stroke and traditional stroke risk factors are…

In the Journals Plus

Starting metformin reduces risks for CV events, death in type 2 diabetes

April 20, 2017
The risks for cardiovascular events and death are decreased 6 months after metformin initiation among adults with type 2 diabetes who experience a…

In the Journals Plus

Declines in CV events, mortality comparable between adults with diabetes, general population

April 17, 2017
Mortality and incidence of cardiovascular outcomes decreased in Sweden from 1998 to 2014 in adults with diabetes. Although rates of nonfatal…

Cardiology Today's top stories covered at the ACC Scientific Session

April 13, 2017
The American College of Cardiology Scientific Session featured important late- break ing clinical trials and other material presented by some of the…

In the Journals Plus

Statin use reduces risk for lower-limb amputation in type 2 diabetes, PAD

April 12, 2017
In adults with type 2 diabetes and peripheral artery disease, statin use was associated with a 25% lower rate of lower-extremity amputations and a…

In the Journals

Revised method in calculating CHD, diabetes risk may lead to increased accuracy

April 11, 2017
An updated method in calculating risk for the development of CHD and diabetes may aid in more accurate predictions, according to findings published…

More Headlines »
Advertisement
Advertisement